Lancet (London, England). 1994 Jun 25;343(8913):1648-9. doi: 10.1016/s0140-6736(94)93107-0 Q188.52025

Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial

转移性结直肠癌完全缓解——多药耐药逆转试验中的陷阱 翻译改进

作者单位 +展开

DOI: 10.1016/s0140-6736(94)93107-0 PMID: 7911960

摘要 中英对照阅读

Copyright © Lancet (London, England). 中文内容为AI机器翻译，仅供参考！

相关内容

• KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem

  结直肠癌转移患者的KRAS位点突变检测：不仅仅是技术问题

  Elin H Kure et al.

  Expert review of molecular diagnostics. 2012 May;12(4):327-8.

• Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases

  转移性结直肠癌化疗性肝损伤48例报告

  Faten Limaiem

  The Pan African medical journal. 2018 Jul 5:30:198.

• Editorial: Optimizing the first-line treatment for metastatic colorectal cancer

  编辑评论：优化转移性结直肠癌的一线治疗方案

  Davide Ciardiello

  Frontiers in oncology. 2024 Jan 24:14:1366383.

• Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer

  帕尼单抗致转移性结直肠癌患者突发性寻常疣状角化病一例报告

  Dimitra Koumaki et al.

  European journal of case reports in internal medicine. 2020 Jan 15;7(2):001411.

• [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]

  转移性结直肠癌中BRAF V600E检测及新出现的、无需化疗的治疗选择

  Michael Hummel et al.

  Der Pathologe. 2021 Nov;42(6):578-590.

• Triple Chemotherapy Combination Improves Metastatic Colorectal Cancer Outcomes

  三种化疗药物联合治疗可改善转移性结直肠癌的预后

  Carrie Printz

  Cancer. 2021 May 15;127(10):1547.

• Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling

  富亮氨酸α-2甘蛋白1通过人表皮生长因子受体3信号促进转移性结直肠癌的生长

  Moeez Rathore et al.

  Gastroenterology. 2024 Oct 10:S0016-5085(24)05566-5.

• Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer

  抗表皮生长因子受体自身抗体与转移性结肠直肠癌的关系

  Anne Kendall

  Recent patents on anti-cancer drug discovery. 2010 Jun;5(2):142-51.